Akero Therapeutics SG&A Expense (Quarterly) Insights

Akero Therapeutics Inc (AKRO)

19.66 -0.05 (-0.25%) USD | NASDAQ | May 03, 16:00

19.64 -0.02 (-0.10%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2018. Upgrade now.

Date	Value
December 31, 2023	8.481M
September 30, 2023	7.981M
June 30, 2023	7.644M
March 31, 2023	6.966M
December 31, 2022	7.10M
September 30, 2022	11.00M
June 30, 2022	6.231M
March 31, 2022	5.537M
December 31, 2021	4.728M
September 30, 2021	4.883M
June 30, 2021	4.99M
March 31, 2021	4.526M

Date	Value
December 31, 2020	4.074M
September 30, 2020	4.159M
June 30, 2020	3.417M
March 31, 2020	3.588M
December 31, 2019	3.083M
September 30, 2019	2.424M
June 30, 2019	1.649M
March 31, 2019	1.449M
December 31, 2018	0.985M
September 30, 2018	0.474M
June 30, 2018	0.242M
March 31, 2018	0.195M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

1.649M

Minimum

Jun 2019

11.00M

Maximum

Sep 2022

5.393M

Average

4.883M

Median

Sep 2021

SG&A Expense (Quarterly) Benchmarks